Skip to main content

Value Stock - Dividend - Research Selection

ISIN: , WKN:

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Wall Street Breakfast: What Moved Markets

2022-12-03
Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify.

Why Is United Therapeutics (UTHR) Up 3.8% Since Last Earnings Report?

2022-12-02
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech firm Catalent to shut down Webster facility in 2023, cut jobs

2022-12-01
The company said it would offer severance and job transition support to the affected employees, and cited economic stresses as a factor in shutting down the plant

Should You Add Catalent (CTLT) to Your Portfolio for the Long-Term?

2022-11-27
Aristotle Capital Boston, LLC, an investment advisor, released its “Small/Mid Cap Equity” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund returned -4.67% net of fees compared to -2.82% return for the Russell 2500 Index. Holdings in Financials, Communication Services, and Materials contributed positively to […]

CarParts and Catalent have been highlighted as Zacks Bull and Bear of the Day

2022-11-16
CarParts and Catalent have been highlighted as Zacks Bull and Bear of the Day.

Bear Of The Day: Catalent (CTLT)

2022-11-16
Earnings estimates have slipped for this stock following the most recent earnings miss.

Here’s Why Catalent (CTLT) Underperformed in the Third Quarter

2022-11-15
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, its Investor Class fund ARTMX returned -2.43%, Advisor Class fund APDMX posted a return of -2.42%, and Institutional Class fund APHMX returned -2.41%, compared to a […]

Top 5 3rd Quarter Trades of Le - GuruFocus.com

2022-11-15
GuruFocus Article or News written by insider and the topic is about:

ClearBridge Investments’ Worst Q3 Performer: Catalent (CTLT)

2022-11-11
ClearBridge Investments, an investment management firm, published its “SMID Cap Growth Strategy” third-quarter 2022 investor letter – a copy of which can be downloaded here. During the third quarter, the ClearBridge SMID Cap Growth Strategy underperformed its Russell 2500 Growth benchmark. On an absolute basis, the Strategy had gains across four of the 10 sectors […]

Catalent, Inc. to Present at the Stephens Annual Investment Conference

2022-11-08
SOMERSET, N.J., November 08, 2022--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will participate at the Stephens Annual Investment Conference on November 16, 2022 at 11:00 a.m. ET.